Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies
Open Access
- 10 August 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (43) , 74434-74450
Abstract
Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignanciesKeywords
This publication has 45 references indexed in Scilit:
- Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progressionOncogene, 2016
- Overexpression of Lysine-Specific Demethylase 1 Is Associated with Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial AdenocarcinomaInternational Journal of Gynecological Cancer, 2015
- A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its InhibitorsMedicinal Research Reviews, 2015
- NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effectOncotarget, 2014
- Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinomaBMC Cancer, 2014
- LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancerBritish Journal of Cancer, 2013
- Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung CancerPLOS ONE, 2012
- Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancersInternational Journal of Cancer, 2010
- Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biologyCarcinogenesis, 2009
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004